A federal jury has answered the central question in the long-running Amitiza antitrust litigation: yes, Takeda improperly delayed generic competition for its constipation drug. On May 18, 2026, a jury in the U.S. District Court for the District of Massachusetts found Takeda liable for delaying generic versions of Amitiza (lubiprostone), awarding $885 million in single damages to drug purchasers who claimed they overpaid for years because a cheaper generic was kept off the market. The verdict is a landmark. It is the first time private antitrust plaintiffs have won a jury verdict in a so-called reverse-payment or “pay-for-delay” case — arriving 13 years after the Supreme Court’s FTC v. Actavis decision opened the door to such claims in 2013.
Every prior private case of this kind either settled before a jury could rule or was lost at trial. To put the scale in perspective, because most antitrust damages are automatically tripled under U.S. law, Takeda’s ultimate exposure could reach roughly $2.4 billion to $2.66 billion once judgment is entered. Takeda has not accepted the outcome. The company says it will vigorously pursue post-trial motions and an appeal, and it stresses that the verdict is not final. Still, the Japanese drugmaker has already revised its FY2025 financial results to book a provision reflecting the verdict — a concrete signal of how seriously the company is treating the potential liability.
Table of Contents
- What Did the Takeda Amitiza Class Action Claim About Delayed Generic Competition?
- How the $885 Million in Damages Breaks Down
- Why This Verdict Matters After FTC v. Actavis
- Who Is Covered, and What Should Purchasers Do?
- Takeda’s Appeal and the Risks Ahead for Class Members
- Where Amitiza Stands Today
- How Amitiza Compares to Other Pay-for-Delay Cases
- Frequently Asked Questions
What Did the Takeda Amitiza Class Action Claim About Delayed Generic Competition?
The case centered on a 2014 patent settlement among Takeda, its collaboration partner Sucampo Pharmaceuticals, and Par Pharmaceutical. Par had challenged the Amitiza patents while seeking FDA approval to sell a generic version of lubiprostone, a drug prescribed for chronic constipation and irritable bowel syndrome with constipation. Rather than litigate the patent fight to the end, the companies settled — and it is the terms of that settlement that plaintiffs put on trial. According to the plaintiffs, the settlement was not an ordinary patent compromise but a payoff. The deal was valued at roughly $210 million through a profit-sharing arrangement tied to an authorized generic, and plaintiffs alleged that this compensation was, in substance, a payment to Par to hold its generic off the market until 2021.
In antitrust terms, that is the classic “reverse payment”: instead of the accused infringer paying the patent holder, the patent holder pays the would-be competitor to stay away. The comparison that matters for consumers is simple. When a generic enters the market, prices typically fall sharply — often by 80 percent or more once multiple generics compete. Every year of delay means brand-level prices for pharmacies, insurers, and patients. The jury concluded that the delay in this case caused hundreds of millions of dollars in overcharges across the drug supply chain.
How the $885 Million in Damages Breaks Down
The $885 million single-damages award is not a single lump sum flowing to one group. It is split across three sets of plaintiffs who occupy different positions in the pharmaceutical supply chain. Roughly $475 million went to the direct purchaser class — primarily wholesalers and distributors that bought Amitiza directly from Takeda. Another $347 million was awarded to individual retailer plaintiffs, large pharmacy chains that opted out of the class to pursue their own claims. The remaining $63 million went to the end payor class, which includes health plans and consumers who paid for the drug at the end of the chain.
Hagens Berman, counsel for the direct purchaser class, announced its portion of the win at $474 million following the trial. Under federal antitrust law, most of these damages are subject to automatic trebling, which is why estimates of Takeda’s total potential liability run to roughly $2.4–2.66 billion once the court enters judgment. There is an important limitation to keep in mind: none of this money is being distributed yet. Trebling occurs at entry of judgment, and Takeda’s promised post-trial motions and appeal could reduce, eliminate, or delay any payout for years. Class members should treat headline numbers as potential recoveries, not checks in the mail.
Why This Verdict Matters After FTC v. Actavis
In 2013, the Supreme Court held in FTC v. Actavis that reverse-payment patent settlements can violate the antitrust laws and must be evaluated under the rule of reason. That decision unleashed a wave of pay-for-delay litigation, but for 13 years, no private plaintiff group managed to win one of these cases in front of a jury. Cases either settled — sometimes for substantial sums — or plaintiffs lost at trial, as juries proved willing to accept drugmakers’ explanations that their settlements were legitimate patent compromises. The Amitiza verdict breaks that pattern.
As antitrust practitioners at firms including Katten and Pierson Ferdinand have noted, it is the first jury verdict for private plaintiffs in a reverse-payment case, and it demonstrates that jurors can be persuaded that a profit-sharing arrangement — not just a cash payment — constitutes an unlawful inducement to delay competition. That matters because modern pharmaceutical settlements rarely involve a simple wire transfer; they use authorized-generic agreements, co-promotion deals, and other structures whose value is harder to see. A concrete example of the stakes: the alleged deal here kept Par’s generic off the market until 2021. For a drug generating hundreds of millions of dollars in annual U.S. sales, several years of exclusivity can be worth far more than the roughly $210 million the settlement was valued at — which is precisely the economic logic plaintiffs argued made the arrangement a payoff rather than a compromise.
Who Is Covered, and What Should Purchasers Do?
The litigation involved three distinct plaintiff groups, and coverage depends on where a purchaser sits in the supply chain. Direct purchasers — companies that bought Amitiza straight from Takeda — are represented in the certified direct purchaser class handled by Hagens Berman and co-counsel. Large retailers with sufficient purchase volumes pursued individual claims outside the class. End payors, including insurers, union health funds, and in some circumstances consumers who paid out of pocket, fall into the end payor class that was awarded $63 million. The practical tradeoff between these paths is worth understanding.
Opt-out retailers took on the cost and risk of their own lawsuits in exchange for controlling their claims and, in this case, securing $347 million — a larger per-plaintiff recovery than they likely would have received through the class. Class members, by contrast, bear no litigation cost and need only file a claim if and when a settlement fund or judgment distribution is established. For most smaller purchasers and health plans, remaining in the class is the only realistic route. For now, the actionable steps are modest: entities that purchased or reimbursed Amitiza between the 2014 settlement and the 2021 generic entry should preserve purchase and reimbursement records, and watch for notices from class counsel or the court about claims procedures. No claim deadline exists until the judgment survives appeal or the parties settle.
Takeda’s Appeal and the Risks Ahead for Class Members
The single biggest caveat in this story is that the verdict is not final. Takeda stated plainly that it will “vigorously pursue post-trial motions and an appeal.” Post-trial motions could ask the district court to overturn the verdict as a matter of law or order a new trial; an appeal to the First Circuit could take years and could challenge everything from the jury instructions to the causation and damages models. Reverse-payment cases involve genuinely unsettled legal questions — particularly how to value non-cash consideration like authorized-generic profit splits — and appellate courts have not hesitated to reverse antitrust judgments on such grounds. That said, Takeda’s own accounting suggests the company sees real risk.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
It revised its FY2025 financial results to record a provision for the verdict, a step companies take when a loss is probable and estimable. Investors and class members alike should read that as an acknowledgment that the exposure is substantial, even as the company fights on. The warning for class members is straightforward: be skeptical of anyone promising quick payouts from this verdict, and be alert to claim-filing scams that often follow large, well-publicized awards. Legitimate distributions will come through court-approved notice from class counsel, not unsolicited calls or emails demanding fees or personal financial information.
Where Amitiza Stands Today
Amitiza itself is no longer a Takeda product. The company’s collaboration and license agreement with Sucampo — the drug’s originator, later acquired by Mallinckrodt — terminated as of March 31, 2024, and Takeda no longer sells or markets the drug in the United States.
Generic lubiprostone has been available since Par’s 2021 launch, meaning patients today pay generic prices regardless of the litigation’s outcome. That timing illustrates a recurring feature of pharmaceutical antitrust cases: the market harm is historical by the time a jury rules. The trial in 2026 addressed conduct rooted in a 2014 settlement and overcharges that largely accrued before 2021 — a reminder that antitrust remedies compensate past injury rather than restore lost competition in real time.
How Amitiza Compares to Other Pay-for-Delay Cases
Before Amitiza, the best-known reverse-payment outcomes came through settlements rather than verdicts. Cases involving drugs such as Cipro, Lipitor, and Nexium produced years of litigation; the Nexium case actually reached a jury in 2014, but the jury found for the defendants, and other matters resolved with negotiated payments that avoided the risk of trial. Against that backdrop, an $885 million plaintiff verdict — with trebling pushing exposure past $2.4 billion — is without precedent in private pay-for-delay litigation, and firms on both sides of the antitrust bar have flagged it as a case that will shape how future patent settlements are structured and defended.
Frequently Asked Questions
What did the jury decide in the Takeda Amitiza antitrust case?
On May 18, 2026, a federal jury in Massachusetts found Takeda liable for delaying generic competition for Amitiza and awarded $885 million in single damages.
Why could Takeda owe more than $885 million?
Under U.S. antitrust law, most damages are automatically trebled at entry of judgment, pushing potential liability to roughly $2.4–2.66 billion.
What conduct was at issue?
A 2014 patent settlement with Par Pharmaceutical, valued at about $210 million through an authorized-generic profit-sharing arrangement, which plaintiffs said paid Par to delay its generic until 2021.
Who receives the damages?
Roughly $475 million goes to the direct purchaser class, $347 million to individual retailer plaintiffs, and $63 million to the end payor class of health plans and consumers.
Is the money being paid out now?
No. Takeda is pursuing post-trial motions and an appeal, so no distribution will occur unless the verdict survives or the case settles.
Does Takeda still sell Amitiza?
No. Its license agreement with Sucampo ended March 31, 2024, and generic lubiprostone has been on the market since 2021.
You Might Also Like
- Wiley Rein Data Breach Class Action Claims Hackers Stole Sensitive Client Information
- Tesla Quebec Heat Pump Class Action Claims Cold-Weather Failures Could Cost Up to $400 Million
- IKEA Tariff Refund Class Action Claims Shoppers Paid Prices Inflated by Unlawful Duties